Weigao Orthopaedics Acquires Controlling Stake in JieSiBaiEr, a Minimally Invasive Spine and Sports Medicine Technology Innovator

Jiesbyer Medical, founded in 2019, is a technology-driven medical technology enterprise specializing in the fields of minimally invasive spinal surgery and sports medicine. Its core businesses focus on two key areas: minimally invasive orthopedic devices and active energy platforms. The company’s core management and R&D team has extensive experience and technical expertise in the medical device industry. It has established a comprehensive product portfolio covering percutaneous spinal endoscopes, orthopedic joint endoscopes, ultrasonic bone scalpels, medical endoscopic camera systems, high-frequency electrosurgical units, and accompanying instruments and consumables. Multiple core products have successfully obtained medical device registration certificates, showcasing strong technological barriers and significant competitive advantages in the industry.

After several years of development, Jiesbyer Medical has accumulated profound technical and industrial value: First, its technological leadership is evident as its self-developed products like ultrasonic osteotomes adopt integrated and unified designs, offering significant advantages in surgical safety, operational convenience, and treatment efficiency, aligning well with clinical needs. Secondly, its core products have completed medical device registration and obtained necessary certifications, laying the groundwork for scaled commercial promotion. Against the backdrop of ongoing deepening of orthopedic centralized procurement policies in China, Jiesbyer Medical’s technology strategy closely matches industry upgrade trends. The company, still in its growth phase, has become a highly promising innovator in China's minimally invasive orthopedic device sector due to its core technology strengths and comprehensive product pipeline.

Daotong Investment Focuses on Healthcare for the Long Term, Deepening Industry Expertise and Supporting Medical Innovation Growth

In the future, Dao Tong Investment will continue to focus on high-growth, high-barrier segments within the healthcare industry. It will prioritize discovering innovative enterprises with core technologies and high industrial value. By empowering through capital and integrating industry resources, it aims to help companies overcome development bottlenecks and achieve high-quality growth. Additionally, it will continuously optimize investment and exit strategies to deliver stable and sustainable returns for all investors.